CompletedNot Applicable

Exercise on Expression of Heat Shock Protein 70 in Arterial Risk

Mexico32 participantsStarted 2019-06-03

Plain-language summary

Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP), among which is Hsp70, to stimulate innate immunity and face stress. Methods: This is a clinical trial where 260 individuals were evaluated by a screening test employing the Ankle-Arm Index (ABI), 220 of them were not within risk value (0.91 to 0.99 mmHg). In the clinical trial, 32 individuals were included. A control group and an experimental group were formed. Aerobic exercise intervention was performed for 12 weeks. The level of Hsp70 was evaluated, physical and clinical measurements were applied at the beginning and at the end of the trial.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Individuals who attended the internal medicine service of the "Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado de Puebla" (ISSSTEP) Hospital were invited to participate voluntarily, from February to September of 2019. In order to detect people at risk of PAD, the measurement of the ABI was done. The measure was taken after 10 minutes of resting. The measure was taken in the four extremities to obtain systolic BP of the posterior tibial artery and brachial artery. The cut point to enter the study was between 0.91 and 0.99 mmHg. The informed consent was signed by all the individuals. Inclusion criteria * ABI cut point from 0.91 to 0.99 * Age, from 40 to 75 years old * Both genders Exclusion criteria * Unable to perform Bruce's stress test * Presence of fractures or sprains in the last 3 months * Diagnosis of diabetes, heart disease, angina pectoris or heart attack

What they're measuring

Impact of exercise on expression of Hsp70 in individuals at risk of peripheral arterial disease

Timeframe: 12 weeks

Trial details

NCT IDNCT04743128

SponsorUniversidad Popular Autónoma del Estado de Puebla

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-30

View on ClinicalTrials.gov More Peripheral Arterial Disease trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.